CA2610416A1 - Inhibiteur de tubuline et sa methode de preparation - Google Patents

Inhibiteur de tubuline et sa methode de preparation Download PDF

Info

Publication number
CA2610416A1
CA2610416A1 CA002610416A CA2610416A CA2610416A1 CA 2610416 A1 CA2610416 A1 CA 2610416A1 CA 002610416 A CA002610416 A CA 002610416A CA 2610416 A CA2610416 A CA 2610416A CA 2610416 A1 CA2610416 A1 CA 2610416A1
Authority
CA
Canada
Prior art keywords
trifluoro
pyrazin
process according
phenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002610416A
Other languages
English (en)
Inventor
David Michael Blum
Yanzhong Wu
Jean Schmid
Timothy John Doyle
Jay Thomas Afragola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth
David Michael Blum
Yanzhong Wu
Jean Schmid
Timothy John Doyle
Jay Thomas Afragola
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37074929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2610416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth, David Michael Blum, Yanzhong Wu, Jean Schmid, Timothy John Doyle, Jay Thomas Afragola filed Critical Wyeth
Publication of CA2610416A1 publication Critical patent/CA2610416A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002610416A 2005-06-13 2006-06-08 Inhibiteur de tubuline et sa methode de preparation Abandoned CA2610416A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69001605P 2005-06-13 2005-06-13
US60/690,016 2005-06-13
US80278106P 2006-05-24 2006-05-24
US60/802,781 2006-05-24
PCT/US2006/022574 WO2006138180A1 (fr) 2005-06-13 2006-06-08 Inhibiteur de tubuline et sa methode de preparation

Publications (1)

Publication Number Publication Date
CA2610416A1 true CA2610416A1 (fr) 2006-12-28

Family

ID=37074929

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002610416A Abandoned CA2610416A1 (fr) 2005-06-13 2006-06-08 Inhibiteur de tubuline et sa methode de preparation

Country Status (12)

Country Link
EP (1) EP1891052A1 (fr)
JP (1) JP2008543838A (fr)
AR (1) AR054392A1 (fr)
AU (1) AU2006259663A1 (fr)
BR (1) BRPI0612145A2 (fr)
CA (1) CA2610416A1 (fr)
GT (1) GT200600257A (fr)
MX (1) MX2007015718A (fr)
PE (1) PE20070114A1 (fr)
SV (1) SV2007002573A (fr)
TW (1) TW200716613A (fr)
WO (1) WO2006138180A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163060B2 (en) 2009-11-12 2015-10-20 R&D Biopharmaceuticals Gmbh Tubulin inhibitors
EP2903436B1 (fr) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Composés hétérocycliques et leur utilisation pour le traitement de tauopathies neurodégénératives
WO2017181974A1 (fr) * 2016-04-20 2017-10-26 苏州苏领生物医药有限公司 Composé hétérocyclique à cinq chaînons, procédé de préparation correspondant, composition pharmaceutique et utilisation
WO2019169111A1 (fr) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania Composés de [1,2,4]triazolo[1,5-a]pyrimidine et utilisation de ces derniers dans la stabilisation de microtubules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030216A1 (fr) * 2003-09-24 2005-04-07 Wyeth Holdings Corporation 5-arylpyrimidines utilisees comme agents anticancereux
ES2279452T3 (es) * 2003-09-24 2007-08-16 Wyeth Holdings Corporation 6-((sustituido)fenil)triazolopirimidinas como agentes antineoplasicos.

Also Published As

Publication number Publication date
EP1891052A1 (fr) 2008-02-27
SV2007002573A (es) 2007-01-03
AR054392A1 (es) 2007-06-20
GT200600257A (es) 2007-02-14
BRPI0612145A2 (pt) 2010-10-19
AU2006259663A1 (en) 2006-12-28
JP2008543838A (ja) 2008-12-04
PE20070114A1 (es) 2007-02-03
WO2006138180A1 (fr) 2006-12-28
TW200716613A (en) 2007-05-01
MX2007015718A (es) 2008-02-21

Similar Documents

Publication Publication Date Title
ES2759480T3 (es) Nuevos derivados de hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
US5856481A (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU2019204745A1 (en) Antimicrobial compounds and methods of making and using the same
EP3173412B1 (fr) Dérivé 7h-pyrrolo[2,3-d]pyrimidine 2,4-disubstituté, procédé de préparation et utilisation médicinale de ce dernier
EP0303697A1 (fr) Derives de la substance physiologiquement active k-252
US20230250087A1 (en) Solid forms of apol1 inhibitor and methods of using same
IL114735A (en) L-Monvalin Aster of 2-) 2-Amino-1,6-Dihydro-6-Oxopurin-9-Il (3-Hydroxy-1-propanol) preparations, preparation
CN115141215A (zh) Kras g12d蛋白抑制剂和其用途
EA025863B1 (ru) Карбазолкарбоксамидные соединения
EP2889287B1 (fr) Dérivé de dolastatine-10, procédé pour le produire et composition de médicament anticancéreux le contenant
US20180370948A1 (en) P-toluenesulfonate for mek kinase inhibitor, method of preparation thereof, and method of use thereof
US9458165B2 (en) DOT1L inhibitors
CA2610416A1 (fr) Inhibiteur de tubuline et sa methode de preparation
KR20060098368A (ko) 항암제로서의 6-[(치환된)페닐]트리아졸로피리미딘
US7501423B2 (en) Tubulin inhibitor and process for its preparation
US11964987B2 (en) Isoidide derivatives and methods of making and using same
US20050124635A1 (en) Process for the preparation of tubulin inhibitors
US20240158404A1 (en) Modulators of alpha-1 antitrypsin
RU2817349C1 (ru) Производные аминопиримидинила
US10617706B2 (en) Compounds for cancer chemotherapeutic sensitization
TW202208371A (zh) 胺基嘧啶基衍生物
JP2024510935A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CN113354590A (zh) 拮抗nod1/2受体信号通路的喹唑啉酮类化合物
WO2022229986A1 (fr) Composés d'indirubine et leurs procédés d'utilisation
WO2021257669A1 (fr) Synthèse d'arylméthylurées substituées, analogues et formes cristallines de celles-ci et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
FZDE Dead